Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 32 | 2023 | 2274 | 3.020 |
Why?
|
Adrenal Cortex Neoplasms | 4 | 2022 | 162 | 1.950 |
Why?
|
Adrenocortical Carcinoma | 3 | 2022 | 88 | 1.690 |
Why?
|
Thyroidectomy | 10 | 2023 | 877 | 1.150 |
Why?
|
Adrenalectomy | 6 | 2022 | 342 | 1.130 |
Why?
|
Thyroid Nodule | 7 | 2019 | 750 | 0.930 |
Why?
|
Adrenal Gland Neoplasms | 5 | 2022 | 740 | 0.910 |
Why?
|
Pyruvates | 1 | 2021 | 87 | 0.800 |
Why?
|
Free Radical Scavengers | 1 | 2019 | 217 | 0.650 |
Why?
|
Acetylcysteine | 1 | 2019 | 272 | 0.630 |
Why?
|
Carcinoma | 8 | 2018 | 2374 | 0.610 |
Why?
|
Proto-Oncogene Proteins B-raf | 10 | 2023 | 2028 | 0.590 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 145 | 0.570 |
Why?
|
Indoles | 5 | 2011 | 1834 | 0.560 |
Why?
|
Parathyroid Neoplasms | 1 | 2018 | 245 | 0.560 |
Why?
|
Carcinoma, Papillary | 9 | 2018 | 781 | 0.530 |
Why?
|
Thyroid Gland | 6 | 2019 | 1172 | 0.480 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 600 | 0.470 |
Why?
|
Sulfonamides | 4 | 2011 | 1932 | 0.460 |
Why?
|
Parathyroidectomy | 2 | 2013 | 235 | 0.450 |
Why?
|
Hyperglycemia | 1 | 2021 | 1368 | 0.410 |
Why?
|
Hypocalcemia | 2 | 2023 | 191 | 0.400 |
Why?
|
Parathyroid Hormone | 4 | 2023 | 1801 | 0.390 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2013 | 155 | 0.390 |
Why?
|
Adenocarcinoma, Follicular | 3 | 2018 | 324 | 0.360 |
Why?
|
Intraoperative Care | 1 | 2013 | 766 | 0.340 |
Why?
|
Patient Selection | 2 | 2018 | 4214 | 0.340 |
Why?
|
Adrenal Glands | 1 | 2011 | 547 | 0.320 |
Why?
|
Adiposity | 1 | 2018 | 1806 | 0.320 |
Why?
|
Adenoma | 1 | 2018 | 2168 | 0.290 |
Why?
|
Carcinoma, Papillary, Follicular | 2 | 2018 | 60 | 0.290 |
Why?
|
Cell Death | 1 | 2011 | 1695 | 0.270 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2021 | 325 | 0.260 |
Why?
|
Glucose | 3 | 2022 | 4391 | 0.250 |
Why?
|
Cell Line, Tumor | 8 | 2022 | 16665 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9185 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2021 | 3557 | 0.230 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5724 | 0.210 |
Why?
|
Retrospective Studies | 19 | 2022 | 77098 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2013 | 0.200 |
Why?
|
Radionuclide Imaging | 2 | 2018 | 2027 | 0.200 |
Why?
|
Cushing Syndrome | 1 | 2021 | 249 | 0.170 |
Why?
|
Signal Transduction | 5 | 2021 | 23387 | 0.170 |
Why?
|
Humans | 50 | 2023 | 742088 | 0.160 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2658 | 0.160 |
Why?
|
Retroperitoneal Space | 1 | 2018 | 172 | 0.160 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2018 | 176 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 11695 | 0.140 |
Why?
|
False Negative Reactions | 1 | 2018 | 587 | 0.140 |
Why?
|
Lactic Acid | 1 | 2022 | 1132 | 0.140 |
Why?
|
Female | 34 | 2022 | 379592 | 0.140 |
Why?
|
Anatomy | 1 | 2017 | 112 | 0.140 |
Why?
|
Biopsy, Fine-Needle | 5 | 2019 | 1093 | 0.140 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 424 | 0.130 |
Why?
|
Preoperative Period | 1 | 2018 | 546 | 0.130 |
Why?
|
Middle Aged | 25 | 2022 | 213127 | 0.130 |
Why?
|
Cytodiagnosis | 2 | 2018 | 435 | 0.130 |
Why?
|
Tumor Burden | 1 | 2021 | 1905 | 0.130 |
Why?
|
Neoplasm Invasiveness | 4 | 2021 | 3612 | 0.130 |
Why?
|
Prognosis | 9 | 2023 | 29010 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8621 | 0.130 |
Why?
|
Ultrasonography | 5 | 2019 | 5978 | 0.120 |
Why?
|
Aged | 19 | 2021 | 162944 | 0.120 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6259 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2021 | 2107 | 0.120 |
Why?
|
Blood Loss, Surgical | 1 | 2018 | 656 | 0.120 |
Why?
|
Iodine Radioisotopes | 1 | 2018 | 1030 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2021 | 2938 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13655 | 0.120 |
Why?
|
Vitamin D Deficiency | 1 | 2023 | 1331 | 0.120 |
Why?
|
Anthropometry | 1 | 2018 | 1350 | 0.110 |
Why?
|
Technetium | 1 | 2013 | 334 | 0.110 |
Why?
|
Intra-Abdominal Fat | 1 | 2018 | 591 | 0.110 |
Why?
|
Hypothyroidism | 1 | 2018 | 659 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2502 | 0.110 |
Why?
|
Immunotherapy | 2 | 2005 | 4414 | 0.110 |
Why?
|
Drug Synergism | 1 | 2016 | 1791 | 0.110 |
Why?
|
Mice | 9 | 2021 | 81045 | 0.100 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2077 | 0.100 |
Why?
|
Mice, SCID | 3 | 2011 | 2715 | 0.100 |
Why?
|
Administration, Oral | 1 | 2019 | 3913 | 0.100 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11001 | 0.100 |
Why?
|
Lung Neoplasms | 4 | 2022 | 13019 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2018 | 1548 | 0.100 |
Why?
|
Hematoma | 2 | 2013 | 755 | 0.100 |
Why?
|
Ultrasonography, Doppler | 1 | 2013 | 458 | 0.100 |
Why?
|
Aged, 80 and over | 12 | 2021 | 57683 | 0.100 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2011 | 165 | 0.090 |
Why?
|
Male | 25 | 2021 | 349538 | 0.090 |
Why?
|
Reoperation | 2 | 2018 | 4200 | 0.090 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2011 | 876 | 0.090 |
Why?
|
Calcium | 3 | 2023 | 5753 | 0.090 |
Why?
|
Mutation | 7 | 2023 | 29717 | 0.090 |
Why?
|
Cell Nucleus | 1 | 2018 | 2968 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11472 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1683 | 0.080 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 709 | 0.080 |
Why?
|
Neck Dissection | 1 | 2010 | 196 | 0.080 |
Why?
|
Thrombospondin 1 | 1 | 2010 | 250 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2018 | 5062 | 0.080 |
Why?
|
Oxidative Stress | 1 | 2019 | 3081 | 0.080 |
Why?
|
Random Allocation | 1 | 2011 | 2425 | 0.070 |
Why?
|
Cell Proliferation | 2 | 2021 | 10472 | 0.070 |
Why?
|
Genes, Tumor Suppressor | 1 | 2011 | 1097 | 0.070 |
Why?
|
Animals | 9 | 2021 | 168561 | 0.070 |
Why?
|
Adult | 17 | 2021 | 213712 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2020 | 62966 | 0.070 |
Why?
|
Laparoscopy | 1 | 2018 | 2121 | 0.070 |
Why?
|
General Surgery | 1 | 2017 | 1633 | 0.070 |
Why?
|
Oligopeptides | 1 | 2011 | 1176 | 0.070 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14720 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6347 | 0.070 |
Why?
|
Imidazoles | 1 | 2011 | 1205 | 0.060 |
Why?
|
Liver | 1 | 2021 | 7470 | 0.060 |
Why?
|
Hyperparathyroidism | 1 | 2006 | 339 | 0.060 |
Why?
|
Parathyroid Glands | 1 | 2006 | 509 | 0.060 |
Why?
|
Drainage | 1 | 2010 | 1140 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2011 | 18006 | 0.060 |
Why?
|
Cell Cycle | 1 | 2011 | 2964 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5171 | 0.060 |
Why?
|
Cell Division | 1 | 2010 | 4564 | 0.060 |
Why?
|
NF-kappa B | 1 | 2011 | 2500 | 0.050 |
Why?
|
RNA-Binding Proteins | 1 | 2011 | 1899 | 0.050 |
Why?
|
Acanthosis Nigricans | 1 | 2021 | 48 | 0.050 |
Why?
|
Cell Survival | 1 | 2011 | 5872 | 0.050 |
Why?
|
Gene Targeting | 1 | 2005 | 880 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 12958 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2915 | 0.050 |
Why?
|
Cost of Illness | 1 | 2010 | 1852 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2023 | 15244 | 0.050 |
Why?
|
Mitotic Index | 1 | 2021 | 172 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6891 | 0.050 |
Why?
|
Genomics | 1 | 2016 | 5692 | 0.050 |
Why?
|
Breast Neoplasms | 2 | 2005 | 20774 | 0.050 |
Why?
|
Weight Loss | 1 | 2011 | 2604 | 0.050 |
Why?
|
Cryosurgery | 1 | 2005 | 453 | 0.040 |
Why?
|
Monitoring, Intraoperative | 1 | 2006 | 953 | 0.040 |
Why?
|
Irritable Mood | 1 | 2021 | 183 | 0.040 |
Why?
|
Body Weight | 1 | 2010 | 4664 | 0.040 |
Why?
|
Neoadjuvant Therapy | 1 | 2010 | 2721 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2005 | 1000 | 0.040 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2021 | 648 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20086 | 0.040 |
Why?
|
Time Factors | 2 | 2018 | 40054 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2017 | 2906 | 0.040 |
Why?
|
MutS Homolog 2 Protein | 1 | 2019 | 200 | 0.040 |
Why?
|
Disease Progression | 2 | 2017 | 13256 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2021 | 657 | 0.040 |
Why?
|
Gene Fusion | 1 | 2021 | 371 | 0.040 |
Why?
|
Radiography, Abdominal | 1 | 2021 | 537 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4839 | 0.040 |
Why?
|
Young Adult | 6 | 2020 | 56350 | 0.040 |
Why?
|
Survival Rate | 2 | 2022 | 12773 | 0.040 |
Why?
|
Cell Line | 1 | 2011 | 15994 | 0.040 |
Why?
|
Amenorrhea | 1 | 2021 | 485 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1021 | 0.040 |
Why?
|
Necrosis | 1 | 2021 | 1643 | 0.040 |
Why?
|
raf Kinases | 1 | 2016 | 122 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2021 | 1769 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39004 | 0.030 |
Why?
|
Pathology, Molecular | 1 | 2019 | 325 | 0.030 |
Why?
|
Risk | 2 | 2019 | 9679 | 0.030 |
Why?
|
Apoptosis | 1 | 2011 | 9715 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2016 | 261 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3585 | 0.030 |
Why?
|
Risk Factors | 2 | 2018 | 72145 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1526 | 0.030 |
Why?
|
Cadaver | 1 | 2017 | 1333 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3471 | 0.030 |
Why?
|
World Health Organization | 1 | 2019 | 1317 | 0.030 |
Why?
|
Cytokines | 2 | 2005 | 7317 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2016 | 732 | 0.030 |
Why?
|
Video Recording | 1 | 2017 | 944 | 0.030 |
Why?
|
Prospective Studies | 4 | 2018 | 53187 | 0.030 |
Why?
|
Adolescent | 5 | 2021 | 85649 | 0.030 |
Why?
|
Transfection | 2 | 2011 | 5892 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2366 | 0.030 |
Why?
|
Graves Disease | 1 | 2013 | 241 | 0.030 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7276 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16331 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15494 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 35342 | 0.020 |
Why?
|
Weight Gain | 1 | 2021 | 2282 | 0.020 |
Why?
|
Transcription Factor RelA | 1 | 2011 | 275 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2011 | 400 | 0.020 |
Why?
|
Seroma | 1 | 2010 | 69 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6534 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 480 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2021 | 3465 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 489 | 0.020 |
Why?
|
Neck | 1 | 2013 | 693 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4187 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
Netherlands | 1 | 2013 | 2170 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2011 | 808 | 0.020 |
Why?
|
Canada | 1 | 2013 | 2061 | 0.020 |
Why?
|
Quality Improvement | 1 | 2023 | 3738 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2005 | 9274 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 23320 | 0.020 |
Why?
|
Genes, p53 | 1 | 2009 | 755 | 0.020 |
Why?
|
United States | 3 | 2021 | 69693 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 40450 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2009 | 2085 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4249 | 0.020 |
Why?
|
Nomograms | 1 | 2006 | 224 | 0.020 |
Why?
|
Body Mass Index | 1 | 2022 | 12695 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4801 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2005 | 315 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2011 | 2203 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 3001 | 0.010 |
Why?
|
Clinical Competence | 1 | 2017 | 4681 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2906 | 0.010 |
Why?
|
RNA Interference | 1 | 2010 | 2890 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2005 | 1368 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12705 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7716 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15194 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12242 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 13921 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8436 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19862 | 0.010 |
Why?
|
Kinetics | 1 | 2006 | 6474 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5212 | 0.010 |
Why?
|
Length of Stay | 1 | 2010 | 6294 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14554 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2005 | 3199 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12946 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2005 | 2133 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2005 | 6382 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2009 | 11363 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21719 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2010 | 8425 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2010 | 9410 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2005 | 5519 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 5522 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2006 | 15056 | 0.010 |
Why?
|
Child | 1 | 2010 | 77478 | 0.000 |
Why?
|